These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 9152970

  • 21. Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small-cell lung cancer: a Cancer and Leukemia Group B study (CALGB 8832).
    Luikart SD, Herndon JE, Hollis DR, MacDonald M, Maurer LH, Crawford J, Clamon GH, Wright J, Perry MC, Ozer H, Green MR.
    Am J Clin Oncol; 1997 Feb; 20(1):24-30. PubMed ID: 9020283
    [Abstract] [Full Text] [Related]

  • 22. Granulocyte-macrophage colony-stimulating factor in association with high-dose chemotherapy (VETOPEC) for childhood solid tumors: a report from the Australia and New Zealand Children's Cancer Study Group.
    McCowage GB, White L, Carpenter P, Lockwood L, Toogood I, Tiedemann K, Shaw PJ.
    Med Pediatr Oncol; 1997 Aug; 29(2):108-14. PubMed ID: 9180912
    [Abstract] [Full Text] [Related]

  • 23. Phase I trial of etoposide, doxorubicin and cisplatin (EAP) in combination with GM-CSF.
    Ford PA, Arbuck SG, Minniti C, Miller LL, DeMaria D, O'Dwyer PJ.
    Eur J Cancer; 1996 Apr; 32A(4):631-5. PubMed ID: 8695266
    [Abstract] [Full Text] [Related]

  • 24. A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study.
    Graziano SL, Valone FH, Herndon JE, Crawford J, Richards F, Rege VB, Clamon G, Green MR.
    Lung Cancer; 1996 Jun; 14(2-3):315-29. PubMed ID: 8794413
    [Abstract] [Full Text] [Related]

  • 25. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer.
    Woll PJ, Hodgetts J, Lomax L, Bildet F, Cour-Chabernaud V, Thatcher N.
    J Clin Oncol; 1995 Mar; 13(3):652-9. PubMed ID: 7533825
    [Abstract] [Full Text] [Related]

  • 26. Double-cycle high-dose chemotherapy with peripheral blood stem cells and hematopoietic growth factor support in patients with advanced solid tumor. A pilot study by the Hong Kong Biotherapy Group.
    Yeung AW, Pang YK, Tsang YC, Wong SW.
    Cancer; 1994 Apr 01; 73(7):1960-70. PubMed ID: 7511042
    [Abstract] [Full Text] [Related]

  • 27. A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies.
    Shaffer DW, Smith LS, Burris HA, Clark GM, Eckardt JR, Fields SM, Weiss GR, Rinaldi DA, Bowen KJ, Kuhn JG.
    Cancer Res; 1993 Dec 15; 53(24):5929-33. PubMed ID: 8261405
    [Abstract] [Full Text] [Related]

  • 28. Failure of granulocyte-macrophage colony-stimulating factor to reduce febrile neutropenia in children with recurrent solid tumors treated with ifosfamide, carboplatin, and etoposide chemotherapy.
    Marina NM, Shema SJ, Bowman LC, Rodman J, Douglass EC, Furman WL, Pappo A, Santana VM, Hudson M, Meyer WH.
    Med Pediatr Oncol; 1994 Dec 15; 23(4):328-34. PubMed ID: 8058003
    [Abstract] [Full Text] [Related]

  • 29. [Clinical study of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced leukopenia].
    Shi YK, Sun Y, Su M.
    Zhonghua Zhong Liu Za Zhi; 1994 Sep 15; 16(5):356-9. PubMed ID: 7895587
    [Abstract] [Full Text] [Related]

  • 30. A randomized phase I study of oral etoposide with or without granulocyte-macrophage colony-stimulating factor for the treatment of patients with advanced cancer.
    Weiss GR, Shaffer DW, DeMoor C, Rinaldi DA, Rodriguez GI, Eckardt JR, Stephens C, Von Hoff DD.
    Anticancer Drugs; 1996 Jun 15; 7(4):402-9. PubMed ID: 8826608
    [Abstract] [Full Text] [Related]

  • 31. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
    Masuda N, Fukuoka M, Kudoh S, Matsui K, Kusunoki Y, Takada M, Nakagawa K, Hirashima T, Tsukada H, Yana T.
    J Clin Oncol; 1994 Sep 15; 12(9):1833-41. PubMed ID: 7521905
    [Abstract] [Full Text] [Related]

  • 32. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial.
    Ravaud A, Chevreau C, Cany L, Houyau P, Dohollou N, Roché H, Soubeyran P, Bonichon F, Mihura J, Eghbali H, Tabah I, Bui BN.
    J Clin Oncol; 1998 Sep 15; 16(9):2930-6. PubMed ID: 9738560
    [Abstract] [Full Text] [Related]

  • 33. Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial).
    Thomas X, Fenaux P, Dombret H, Delair S, Dreyfus F, Tilly H, Vekhoff A, Cony-Makhoul P, Leblond V, Troussard X, Cordonnier C, de Revel T, Simon M, Nicolini F, Stoppa AM, Janvier M, Bordessoule D, Rousselot P, Ffrench M, Marie JP, Archimbaud E.
    Leukemia; 1999 Aug 15; 13(8):1214-20. PubMed ID: 10450749
    [Abstract] [Full Text] [Related]

  • 34. Placebo controlled phase I/II study of subcutaneous GM-CSF in patients with germ cell tumors undergoing chemotherapy.
    Jost LM, Pichert G, Stahel RA.
    Ann Oncol; 1990 Nov 15; 1(6):439-42. PubMed ID: 1707298
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer.
    Masuda N, Matsui K, Negoro S, Takifuji N, Takeda K, Yana T, Kobayashi M, Hirashima T, Kusunoki Y, Ushijima S, Kawase I, Tada T, Sawaguchi H, Fukuoka M.
    J Clin Oncol; 1998 Oct 15; 16(10):3329-34. PubMed ID: 9779709
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.